Edition:
United States

Immunovaccine Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

1.81CAD
20 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.81
Open
$1.81
Day's High
$1.83
Day's Low
$1.79
Volume
52,286
Avg. Vol
113,971
52-wk High
$2.55
52-wk Low
$1.04

Chart for

About

Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $248.21
Shares Outstanding(Mil.): 137.13
Dividend: --
Yield (%): --

Financials

  IMV.TO Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.10 -- --
ROI: -87.52 -0.74 13.19
ROE: -180.53 -2.80 15.00

BRIEF-Immunovaccine Announces $12.5 Million Bought Deal Offering

* IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE Source text for Eikon: Further company coverage:

Jan 25 2018

BRIEF-Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer

* IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER

Dec 05 2017

BRIEF-IMMUNOVACCINE AND LEIDOS EXPAND COLLABORATION TO DEVELOP MALARIA VACCINE CANDIDATES

* IMMUNOVACCINE AND LEIDOS EXPAND COLLABORATION TO DEVELOP MALARIA VACCINES FORMULATED IN DEPOVAX Source text for Eikon: Further company coverage:

Nov 21 2017

BRIEF-Immunovaccine reports qtrly loss per share of ‍$0.02​

* Immunovaccine announces third quarter 2017 financial results

Nov 09 2017

BRIEF-Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac

* Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL Source text for Eikon: Further company coverage:

Nov 08 2017

Earnings vs. Estimates